BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

837 related articles for article (PubMed ID: 24874200)

  • 21. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy.
    Shen L; Ramires F; Martinez F; Bodanese LC; Echeverría LE; Gómez EA; Abraham WT; Dickstein K; Køber L; Packer M; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Jhund PS; Gimpelewicz CR; McMurray JJV;
    Circ Heart Fail; 2017 Nov; 10(11):. PubMed ID: 29141857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).
    Kristensen SL; Mogensen UM; Jhund PS; Petrie MC; Preiss D; Win S; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Gottdiener JS; Carson PE; McMurray JJ
    Circulation; 2017 Feb; 135(8):724-735. PubMed ID: 28052977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
    Tromp J; Shen L; Jhund PS; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Køber L; Swedberg K; Zile MR; Pitt B; Lam CSP; McMurray JJV
    J Am Coll Cardiol; 2019 Aug; 74(5):601-612. PubMed ID: 31370950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).
    Wong CM; Hawkins NM; Jhund PS; MacDonald MR; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Petrie MC; McMurray JJ
    J Am Coll Cardiol; 2013 Nov; 62(20):1845-54. PubMed ID: 23850914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial.
    Florea VG; Rector TS; Anand IS; Cohn JN
    Circ Heart Fail; 2016 Jul; 9(7):. PubMed ID: 27413037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.
    Kao DP; Lewsey JD; Anand IS; Massie BM; Zile MR; Carson PE; McKelvie RS; Komajda M; McMurray JJ; Lindenfeld J
    Eur J Heart Fail; 2015 Sep; 17(9):925-35. PubMed ID: 26250359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial.
    Chatur S; Vaduganathan M; Claggett BL; Cunningham JW; Docherty KF; Desai AS; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez FA; Shah SJ; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
    Circulation; 2023 Nov; 148(22):1735-1745. PubMed ID: 37632455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).
    Komajda M; Carson PE; Hetzel S; McKelvie R; McMurray J; Ptaszynska A; Zile MR; Demets D; Massie BM
    Circ Heart Fail; 2011 Jan; 4(1):27-35. PubMed ID: 21068341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.
    Lupón J; Díez-López C; de Antonio M; Domingo M; Zamora E; Moliner P; González B; Santesmases J; Troya MI; Bayés-Genís A
    Eur J Heart Fail; 2017 Dec; 19(12):1615-1623. PubMed ID: 28387002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach.
    Hage C; Michaëlsson E; Linde C; Donal E; Daubert JC; Gan LM; Lund LH
    Circ Cardiovasc Genet; 2017 Feb; 10(1):. PubMed ID: 28100627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
    Yusuf S; Pfeffer MA; Swedberg K; Granger CB; Held P; McMurray JJ; Michelson EL; Olofsson B; Ostergren J;
    Lancet; 2003 Sep; 362(9386):777-81. PubMed ID: 13678871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients.
    Solomon SD; Anavekar N; Skali H; McMurray JJ; Swedberg K; Yusuf S; Granger CB; Michelson EL; Wang D; Pocock S; Pfeffer MA;
    Circulation; 2005 Dec; 112(24):3738-44. PubMed ID: 16330684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF.
    Verma AK; Sun JL; Hernandez A; Teerlink JR; Schulte PJ; Ezekowitz J; Voors A; Starling R; Armstrong P; O'Conner CM; Mentz RJ
    Clin Cardiol; 2018 Jul; 41(7):945-952. PubMed ID: 29781109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial.
    Rector TS; Carson PE; Anand IS; McMurray JJ; Zile MR; McKelvie RS; Komajda M; Kuskowski M; Massie BM;
    Circ Heart Fail; 2012 Mar; 5(2):217-25. PubMed ID: 22267751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
    Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Value of Pulmonary Transit Time by Cardiac Magnetic Resonance on Mortality and Heart Failure Hospitalization in Patients With Advanced Heart Failure and Reduced Ejection Fraction.
    Houard L; Amzulescu MS; Colin G; Langet H; Militaru S; Rousseau MF; Ahn SA; Vanoverschelde JJ; Pouleur AC; Gerber BL
    Circ Cardiovasc Imaging; 2021 Jan; 14(1):e011680. PubMed ID: 33438438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physical activity measured with implanted devices predicts patient outcome in chronic heart failure.
    Conraads VM; Spruit MA; Braunschweig F; Cowie MR; Tavazzi L; Borggrefe M; Hill MR; Jacobs S; Gerritse B; van Veldhuisen DJ
    Circ Heart Fail; 2014 Mar; 7(2):279-87. PubMed ID: 24519908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study.
    Kontogeorgos S; Thunström E; Johansson MC; Fu M
    Int J Cardiol; 2017 Apr; 232():86-92. PubMed ID: 28100428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.